Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 86.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,301 shares of the company's stock after selling 21,292 shares during the period. SG Americas Securities LLC's holdings in Medpace were worth $1,006,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Abacus FCF Advisors LLC increased its holdings in shares of Medpace by 72.7% in the first quarter. Abacus FCF Advisors LLC now owns 16,459 shares of the company's stock valued at $5,015,000 after purchasing an additional 6,931 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after buying an additional 83 shares during the period. Portside Wealth Group LLC lifted its holdings in Medpace by 17.7% in the first quarter. Portside Wealth Group LLC now owns 1,063 shares of the company's stock valued at $324,000 after acquiring an additional 160 shares during the last quarter. Park Avenue Securities LLC grew its position in Medpace by 1.8% in the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after acquiring an additional 48 shares during the period. Finally, UMB Bank n.a. increased its stake in Medpace by 70.7% during the first quarter. UMB Bank n.a. now owns 490 shares of the company's stock worth $149,000 after acquiring an additional 203 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 1.6%

MEDP traded up $4.77 during trading hours on Wednesday, hitting $302.69. 656,130 shares of the company's stock were exchanged, compared to its average volume of 364,552. The firm has a market cap of $8.70 billion, a P/E ratio of 23.11, a price-to-earnings-growth ratio of 5.43 and a beta of 1.47. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The firm has a 50 day moving average of $299.23 and a 200 day moving average of $322.10.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same period last year, the firm earned $3.20 earnings per share. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on MEDP shares. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Mizuho lowered their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Finally, TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $349.30.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.